TY - JOUR
T1 - Effects of a-Tocopherol and Mixed Tocopherol Supplementation on Markers of Oxidative Stress and Inflammation in Type 2 Diabetes
AU - Wu, Jason
AU - Ward, Natalie
AU - Indrawan, Adeline
AU - Almeida, C-A.
AU - Hodgson, Jonathan
AU - Proudfoot, Julie
AU - Puddey, Ian
AU - Croft, Kevin
PY - 2007
Y1 - 2007
N2 - Background: Vitamin E isomers may protect against atherosclerosis. The aim of this study was to compare the effects of supplementation with either alpha-tocopherol (alpha T) or mixed tocopherols rich in gamma-tocopherol (gamma T) on markers of oxidative stress and inflammation in patients with type 2 diabetes.Methods: In a double-blind, placebo-controlled trial, 55 patients with type 2 diabetes were randomly assigned to receive (500 mg/day) (a) alpha T, (b) mixed tocopherols, or (0 placebo for 6 weeks. Cellular tocopherols, plasma and urine F-2-isoprostanes, erythrocyte antioxidant enzyme activities, plasma inflammatory markers, and ex vivo assessment of eicosanoid synthesis were analyzed pre- and postsupplementation.Results: Neutrophil alpha T and gamma T increased (both P < 0.001) with mixed tocopherol supplementation, whereas alpha T (P < 0.001) increased and gamma T decreased (P < 0.005) after alpha T supplementation. Both alpha T and mixed tocopherol supplementation resulted in reduced plasma F-2-isoprostanes (P < 0.001 and P = 0.001, respectively) but did not affect 24-h urinary F-2-isoprostanes or erythrocyte antioxidant enzyme activities. Neither aT nor mixed tocopherol supplementation affected plasma C-reactive protein, interleukin 6, tumor necrosis factor-alpha, or monocyte chemoattractant protein-1. Stimulated neutrophil leukotriene B-4 production decreased significantly in the mixed tocopherol group (P = 0.02) but not in the alpha T group (P = 0.15).Conclusions: The ability of tocopherols to reduce systemic oxidative stress suggests potential benefits of vitamin E supplementation in patients with type 2 diabetes. In populations with well-controlled type 2 diabetes, supplementation with either alpha T or mixed tocopherols rich in gamma T is unlikely to confer further benefits in reducing inflammation. (c) 2007 American Association for Clinical Chemistry.
AB - Background: Vitamin E isomers may protect against atherosclerosis. The aim of this study was to compare the effects of supplementation with either alpha-tocopherol (alpha T) or mixed tocopherols rich in gamma-tocopherol (gamma T) on markers of oxidative stress and inflammation in patients with type 2 diabetes.Methods: In a double-blind, placebo-controlled trial, 55 patients with type 2 diabetes were randomly assigned to receive (500 mg/day) (a) alpha T, (b) mixed tocopherols, or (0 placebo for 6 weeks. Cellular tocopherols, plasma and urine F-2-isoprostanes, erythrocyte antioxidant enzyme activities, plasma inflammatory markers, and ex vivo assessment of eicosanoid synthesis were analyzed pre- and postsupplementation.Results: Neutrophil alpha T and gamma T increased (both P < 0.001) with mixed tocopherol supplementation, whereas alpha T (P < 0.001) increased and gamma T decreased (P < 0.005) after alpha T supplementation. Both alpha T and mixed tocopherol supplementation resulted in reduced plasma F-2-isoprostanes (P < 0.001 and P = 0.001, respectively) but did not affect 24-h urinary F-2-isoprostanes or erythrocyte antioxidant enzyme activities. Neither aT nor mixed tocopherol supplementation affected plasma C-reactive protein, interleukin 6, tumor necrosis factor-alpha, or monocyte chemoattractant protein-1. Stimulated neutrophil leukotriene B-4 production decreased significantly in the mixed tocopherol group (P = 0.02) but not in the alpha T group (P = 0.15).Conclusions: The ability of tocopherols to reduce systemic oxidative stress suggests potential benefits of vitamin E supplementation in patients with type 2 diabetes. In populations with well-controlled type 2 diabetes, supplementation with either alpha T or mixed tocopherols rich in gamma T is unlikely to confer further benefits in reducing inflammation. (c) 2007 American Association for Clinical Chemistry.
U2 - 10.1373/clinchem.2006.076992
DO - 10.1373/clinchem.2006.076992
M3 - Article
SN - 0009-9147
VL - 53
SP - 511
EP - 519
JO - Clinical Chemistry
JF - Clinical Chemistry
IS - 3
ER -